Nephrocare Health Services Limited IPO Details

Incorporated in 2010, Nephrocare Health Services Ltd. provides end-to-end dialysis care through a wide network of clinics across India and select international markets. The company offers services including diagnosis, haemodialysis, home and mobile dialysis, and wellness programs, supported by an in-house pharmacy.

As of March 31, 2025, Nephrocare operated 490 clinics—447 in India and 43 across the Philippines, Uzbekistan, and Nepal. This includes the world’s largest dialysis clinic in Uzbekistan. In India, the company had a presence across 269 cities in 21 States and four Union Territories. Approximately 76.73% of its clinics were located in tier II and tier III cities, addressing a critical need in underserved regions.

During Fiscal 2025, Nephrocare served 29,281 patients and completed over 2.88 million dialysis treatments, accounting for roughly 10% of the country's total dialysis patient base. The company managed 5,068 dialysis machines as of March 2025, up from 4,714 in Fiscal 2024 and 3,662 in Fiscal 2023.

Nephrocare has formed strategic partnerships with established hospital chains such as Max Super Speciality Hospital, Fortis Escorts Hospitals, Care Hospitals, Wockhardt Hospitals, Paras Healthcare, The Calcutta Medical Research Institute, Jehangir Hospital, and Ruby Hall Clinic to operate in-house dialysis centers.

As of March 2025, the workforce included 3,230 employees encompassing both medical and administrative staff working across its clinics and corporate office.